Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

Experts Discuss How They Use Asciminib in Their CML Practice

MyCancerHaven

R. Vij, J. Zeidner

Efficacy and Safety of Asciminib in Ph+ CML

Luke Fletcher

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes Among Pat…

Insights from 2023 ASH Annual Meeting

E. Atallah

Current Treatment Landscape in Myeloid Malignancies

Houston Methodist

S. Shah

Updates on Myeloproliferative Neoplasms Including CML

Winship Cancer Institute - Emory University

A. Hunter

Treating Fibrosis and Inflammation in GvHD

Pooja Khandelwal

Controversies in the Management of CML in 2024

Indy Hematology Review

R. Larson

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

SOHO 2023 Eleventh Annual Meeting

N. Cross

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

City of Hope

I. Amanam

Highlights of Recent Updates in CML: Impact on Practice

2024 ASCO® Annual Meeting Insights Hub

E. Atallah

How I Treat R/R CML in 2024: Strategies and Emerging Therapies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

Biological Highlights in CML From EHA

International CML Foundation

N. Cross

Clinical Highlights in CML From EHA

International CML Foundation

A. Hochhaus

Understanding and Addressing the Challenges in CML in 2024

Indy Hematology Review

R. Larson

TKI Discontinuation in CML: Defining Eligibility Criteria and Predic…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Yassin

SOHO 2023: CML - Are We Doing It Right?

SOHO 2023 Eleventh Annual Meeting

J. Cortés